• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by DICE Therapeutics Inc.

    8/9/23 9:45:54 AM ET
    $DICE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DICE alert in real time by email
    S-8 POS 1 d539640ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on August 9, 2023

    Registration No. 333-259565

    Registration No. 333-263901

    Registration No. 333-270563

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-259565

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-263901

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-270563

    Under

    The Securities Act of 1933

     

     

    DICE THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   47-2286244

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    400 East Jamie Court, Suite 300

    South San Francisco, California

      94080
    (Address of Principal Executive Offices)   (Zip Code)

    2021 Equity Incentive Plan

    2021 Employee Stock Purchase Plan

    (Full title of the plan)

    Philip L. Johnson

    President

    DICE Therapeutics, Inc.

    Lilly Corporate Center

    Indianapolis, Indiana 46285

    (Name and address of agent for service)

    (317) 276-2000

    (Telephone number, including area code, of agent for service)

    Copy to:

    Sophia Hudson, P.C.

    Julia Danforth

    Kirkland & Ellis LLP

    601 Lexington Avenue

    New York, New York 10022

    Telephone: (212) 446-4800

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     


    DEREGISTRATION OF SECURITIES

    These Post-Effective Amendments (these “Post-Effective Amendments”) filed by DICE Therapeutics, Inc. (the “Registrant”) relate to the following registration statements on Form S-8 (together, the “Registration Statements”):

     

    1.

    Registration Statement No. 333-259565, registering an aggregate of 6,564,332 shares of the Registrant’s common stock, $0.0001 par value per share (the “Common Stock”), consisting of (i) 6,189,332 shares of Common Stock issuable under the 2021 Equity Incentive Plan (the “2021 EIP”) and (ii) 375,000 shares of Common Stock issuable under the Registrant’s 2021 Employee Stock Purchase Plan (the “2021 ESPP”), which was filed with the U.S. Securities and Exchange Commission (the “Commission”) on September 15, 2021;

     

    2.

    Registration Statement No. 333-263901, registering an aggregate of 2,293,458 shares of Common Stock consisting of (i) 1,911,215 shares issuable under the 2021 EIP and (ii) 382,243 shares issuable under the 2021 ESPP, which was filed with the Commission on March 28, 2022; and

     

    3.

    Registration Statement No. 333-270563, registering an aggregate of 2,862,460 shares of Common Stock consisting of (i) 2,385,384 shares issuable under the 2021 EIP and (ii) 477,076 shares issuable under the 2021 ESPP, which was filed with the Commission on March 15, 2023.


    On August 9, 2023, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2023 (the “Merger Agreement”), by and among the Registrant, Eli Lilly and Company (“Parent”) and Durning Acquisition Corporation (“Purchaser”), Purchaser merged with and into the Registrant (the “Merger”), with the Registrant surviving such Merger as a wholly-owned subsidiary of Parent. As a result of the transactions contemplated by the Merger Agreement, the Registrant has terminated any and all offerings and sales of securities pursuant to the Registration Statements. In accordance with the undertakings made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities of the Registrant registered under the Registration Statements which remain unsold at the termination of the offering, the Registrant hereby terminates the effectiveness of the Registration Statements and removes from registration all of the securities that remain unsold under the Registration Statements as of the date hereof, if any.

    The Registrant is filing these Post-Effective Amendments to withdraw and remove from registration all securities registered pursuant to the Registration Statements that remain unsold as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities. After giving effect to these Post-Effective Amendments, there will be no remaining securities registered by the Registrant pursuant to the Registration Statements.


    SIGNATURE

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Indianapolis, Indiana, on August 9, 2023.

     

    DICE THERAPEUTICS, INC.
    By:  

    /s/ Philip L. Johnson

    Name:   Philip L. Johnson
    Title:   President

    Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign these Post-Effective Amendments.

    Get the next $DICE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DICE

    DatePrice TargetRatingAnalyst
    5/24/2023$38.00Equal Weight
    Wells Fargo
    5/22/2023$71.00Buy
    Canaccord Genuity
    3/31/2023$56.00Buy
    Needham
    3/1/2023Outperform
    TD Cowen
    3/1/2023Outperform
    Cowen
    11/15/2022$65.00Buy
    Guggenheim
    9/14/2022$36.00Overweight
    Cantor Fitzgerald
    9/7/2022$37.00Buy
    Stifel
    More analyst ratings